

## Curriculum Vitae

**Name:** Zari – Nokhodian Esfahani

**Address:** Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

**Education:**

MSc in Toxicology; Isfahan University of Medical Sciences, Isfahan, Iran: 2008-2011

Ph.D. in Biomedicine; Isfahan University of Medical Sciences, Isfahan, Iran:2012-2017

**Thesis topics for MS:** Genotoxic effects of some 1-[(benzofuran-2-yl)-phenylmethyl] imidazoles on MCF-7 cell line.

**Thesis topics for PhD:** The Assessment of Seroepidemiology and Molecular Epidemiology of *Coxiella Burnetii* in Ruminant, Milk and Q Fever High-Risk Populations and Comparison of Detected Genotypes in Isfahan in 2015.

**Professional experience:**

Manager of Infectious Diseases and Tropical Medicine Research Center. 2000- present.

Research assistant of Infectious Diseases and Tropical Medicine Research Center. 2000-present

**E-mail:** Nokhodian@ yahoo.com

**Project:**

1. Head project in: The Comparison of Quality of life between Patients with Chronic liver disease arising from hepatitis B and C and Control Group in 2004 - 2005.
2. Head project in: The Assessment of the Relative frequency of prevalence of HBV, HCV, HIV in Street Children and teenager in Isfahan city in 2005-2006.
3. Head project in: The prevalence of hepatitis A, B and E Virus in Isfahan in 2005-2006.
4. Head project in: The Assessment and comparison of risk factors in B and C hepatic patients referred to Infectious Diseases Research Center and Control group referred to Endocrinal and Metabolism Research Center.
5. Head project in: The assessment of the relative frequency of prevalence of HBV, HCV and HIV in incarcerated juvenile in Isfahan in 2006.
6. Head project in: The Assessment of the relative frequency of prevalence of HAV in Street Children and teenager in Isfahan city.
7. Head project in: Prevalence of HBV, HCV, HIV and syphilis among female prisoners in Isfahan, Iran.
8. Head project in: Prevalence of HIV infection in cases with previous history of intravenous drug abuse by community-based announcement.
9. Head project in: The assessment serology of *Coxiella burnetii* in butchers in Isfahan in 2015.

10. Head project in: The assessment of seroepidemiology of *Coxiella burnetii* in farmers in Isfahan in 2015.
11. Head project in: The assessment of molecular epidemiology of *Coxiella burnetii* in cow milk in Isfahan in 2015.
12. Head project in: The assessment of molecular epidemiology of *Coxiella burnetii* in ruminant in Isfahan in 2015.
13. Head project in: The assessment of genotypes of *Coxiella burnetii* in ruminant, Milk and Q fever high-risk populations in Isfahan in 2015.
14. Head project in: Investigation of the Antibacterial Effects of biosynthesized Nano silver from Iran's pistachio hulls on antibiotic resistant *Acinetobacter* and *Pseudomonas*.
15. Head project in: Bacterial co-infection and antibiotic management in patients with COVID-19 admitted to Intensive care medicine in central Iran: A follow-up study.
16. Head project in: Assessment of incidence of bacterial urinary tract infections and its risk factors in patients admitted to hospitals in Isfahan province in 2017-2021
17. Co-operate in: Prevalence of infectious rate and identification of *Brucella* species in raw milk with Real time PCR system in Isfahan city.
18. Co-operate in: Assessment of HIV & HCV co infection in IVDUs in Isfahan Province.
19. Co-operate in: Prevalence and associated risk factors of hepatitis B Infection in IVDU prison Inmates in Isfahan Province.
20. Co-operate in: The Seroepidemiology of HBV infection and associated risk factors in DICs' IVDUs in Isfahan Province-2011.
21. Co-operate in: Prevalence of infectious rate and identification of *Brucella* species in dairy product with Real time PCR system in Isfahan city in 1389.
22. Co-operate in: The Assessment and comparison of HBS – Antibody rate in type 2 diabetic and non-diabetic subjects after hepatitis B vaccination – 2003.
23. Co-operate in: The Comparison of seroprevalence of *Helicobacter Pylori* in type 2 Diabetic and nondiabeticSubjects-2003.
24. Co-operate in: The prevalence of Anti HAV (IgG) in patient with chronic Hepatitis B & C in tropical medicine research centers to compare with HAV in Isfahan.
25. Co-operate in: Prevalence of Hepatitis B and their Risk Factors in Transit Heavy Vehicle Drivers -2007.
26. Co-operate in: "The assessment and management of hepatitis C in IVDA in Isfahan province" 2008.
27. Co-operate in: The prevalence of Toxoplasmosis in Isfahan province.
28. Co-operate in: The prevalence of cytomegalovirus infection in people in Isfahan province.
29. Co-operate in: A pilot study for Surveillance of acute respiratory infections among outpatients in Isfahan city (2009-2010) .
30. Co-operate in: Prevalence of hepatitis B, C, HIV infections and HBs antibody titer among private and governmental laboratories' staff in Esfahan city in 2009-2010.

31. Co-operate in: Comparison assessment of result biopsies of liver with Hepascore in patients genotypes 1.
32. Co- operate in: Evaluation of the frequency of genetic resistance to Lamivudine and Adefovir in treatment naïve patients with chronic hepatitis B infection: a pilot study.
33. Co-operate in: The Establishment of the first primary immunodeficiency Biobank in Isfahan University of Medical Sciences.
34. Co-operate in: Seroepidemiology and Risk Factors of HIV Infection in Prison's IVDUs in Isfahan Province.
35. Co- operate in: The prevalence and Associated Risk factors of HIV Infection in Drop in Centers (DIC) in Isfahan Province.
36. Co project in: Hepatitis C in individuals with drug injection history in Golpayegan city-2008.
37. Co project in: Hepatitis C in IVDA inmates in Asadabad prison Isfahan province -2008.
38. Co project in: Hepatitis C in Multi transfused patients in Isfahan, 2008
39. Co project in: Hepatitis C in individuals with drug injection history in Tiran city-2008.
40. Co project in: The assessment of hepatitis B seroprevalence in persons with IVDU history in the Isfahan province: Community-based study
41. Co project in: Hepatitis C in IVDA inmates in Isfahan province -2008.
42. Co project in: Prevalence of total anti HBS antibody in HBS Ag negative in hemodialysis patients in Isfahan city
43. Co project in: The Assessment of Nutritional and Antropometric Status and their relationship with CD4+ Count in HIV+/AIDS patients in Isfahan Referred to Navab Safavi Medical Center -2005.
44. Co project in: The assessment of the effects of zinc supplement on T- Lymphocyte profiles in patients with Aids referred to Navab- safavi medical center -2005
45. Co project in: Intestinal parasitosis in HIV patients referred to Navab- safavi medical center.
46. Co project in: Evaluation of immunity against measles, mumps, rubella and pertussis in students aged 7-18 in Iran.
47. Co project in “The Effect of Education Based on Educational Campaign on Knowledge, Attitude and Practice of Antibiotic Use and Microbial Resistance in Isfahan.
48. Co project in “The Experience of antibiotic campaign in Isfahan: A phenomenology qualitative study-2019
49. Co project in “Investigation of the relative frequency of IgG and IgM antibodies against SARS-CoV-2 virus in the blood serum of Isfahan Mobarakeh Steel Company personnel in the spring of 1399 (industrial project).
50. Co project in Investigating the trend of changing antibiotic resistance in selected hospitals in Isfahan before, during and after the COVID-19 pandemic in Iran.
51. Co project in” Investigation of the frequency distribution of isolated organisms in brain shunt infection and their antibiotic susceptibility patterns in patients of Al-Zahra and Kashani hospitals in Isfahan in 2016-2017.
52. Co project in “Healthcare-associated infections and sepsis registration program in Intensive Care Units”

**Article:**

1. Ataei B, Khademi M, Sadeghi A, **Nokhodian Z**, Kasaeian N. Survey of hepatitis B risk factors in blood donors at Isfahan Province. *Blood* 2005; 2 :183-188.
2. Shadzi M, Karbassian A, Khademi M, Kasaian N, **Nokhodian Z**, Chabavizadeh J. The prevalence of etiological agents of dermatophytoses in wrestlers of Isfahan. *Journal of Isfahan Medical school* 2005; 78: 77-80.
3. **Nokhodian Z**, Ataei B. The correlation between HBS-Ag and Alanine Aminotransferase level in chronic hepatitis B with PCR positive patients. *Iranian journal of infectious diseases and tropical medicine* 2006; 32: 29-33.
4. Khademi MR, Amini M, Ataei B, Kasaeian N, **Nokhodian Z**, Shoaie P. Comparison of ABs-antibody Serum Levels between Patients with Type 2 Diabetes Mellitus and Controls Following Vaccination against Hepatitis B. *Journal of Isfahan Medical school* 2007; 84: 65-70.
5. Ataei B, **Nokhodian Z**, Javadi AA, Kassaian N, Shoaie P, Farajzadegan Z, Adibi P. Hepatitis E Virus in Isfahan province: a population-based study. *Int J Infect Dis* 2009; 13: 67-71.
6. Ataei B, Javadi AA, **Nokhodian Z**, Kassaian N, Shoaie P, Farajzadegan Z, Adibi P. HAV in Isfahan province: a population-based study. *Tropical Gastroenterology* 2008; 29 (3): 160-162.
7. Javadi A, Shafei M, Ataei B, **Nokhodian Z**. Assessment of prevalence of the antibodies in Isfahan in 1384. *Homa-ye-salamat* 2008; 4: 24-28.
8. **Nokhodian Z**, Kassaian N, Ataei B, Javadi AA, Shoaie P, Farajzadegan Z, Adibi P. Hepatitis B Markers in Isfahan, Central Iran: A Population-Based Study. *Hepatitis Monthly* 2009; 9(1): 12-16.
9. **Nokhodian Z**, Ataei B, Adibi P, FarajZadegan Z, Rostami S. Comparison of Quality of Life in Hepatitis B & Hepatitis C Patients. *Journal of Isfahan Medical School* 2009; 598-604.
10. Khademi MR, Amini M, Ataei B, **Nokhodian Z**, Akbari M, Shoaie P, Kasaeian N, Noroozy A. Is the Prevalence of Helicobacter Pylori Infection Different in Type II Diabetes Mellitus Patients and Non-Diabetic Individuals? *Journal of Isfahan Medical school* 2009; 504-498.
11. Ataei B, Ansari M, Yaran M, **Nokhodian Z**, Nejati H, Farajzadegan Z, Kasaeian N. The Prevalence of Hepatitis B, Hepatitis C and their Risk Factors in Transit Heavy Vehicle Drivers in Isfahan, Iran. *Journal of Isfahan Medical school* 2009;475-468.
12. Javadi AA, Ataei B, Shafei M, **Nokhodian Z**. Evaluation of satisfaction and its factors in patients in Emergency Departments of Isfahan province in 2005. *Journal of Homa-ye-salamat* 2008; 25: 17-21.
13. **Nokhodian Z**, Ataei B, Kassaian N, Adibi P, Farajzadegan Z. Assessment of quality of life in hepatitis B patients in Iran. *Indian J, Gastroenterol* 2009; 23 (3): 115-119.
14. Tayeri K, Radfar SR, Yaran M, Kassaian N, **Nokhodian Z**, Ataei B, Fadaei R. Isolation of Hepatitis C virus in Norgestic. *Hepatitis Monthly* 2010; 10 (1): 65-66.

15. Ataei B, **Nokhodian Z**, Babake A, Shoaie P, Mohammad Zadeh M, Sadeghi S. Seroprevalence and associated Risk Factors of hepatitis B virus among street children in Isfahan, Iran. *Journal of Isfahan Medical School* 2010; 102: 788-797.
16. Ataei B, **Nokhodian Z**, Babake A, Shoaie P, Mohammad Zadeh M, Sadeghi S. Seroprevalence of Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) infection among street children in Isfahan, Iran. *Tehran University Medical Journal* 2010; 11: 811-816.
17. **Nokhodian Z**, Ataei B, Yaran M, Shams A, Kassaian N, Kafashian AR, Ehsani M, Adibi P. Hepatitis C in Correctional Centers: A Useful Experience. *Journal of Isfahan Medical School* 2011; 28(Special Issue on Hepatitis C):1577-80.
18. Ataei B, Babak A, Yaran M, Kassaian N, **Nokhodian Z**, Meshkati M, Adibi P. Hepatitis C in Intravenous Drug Users: Seroprevalence and Risk Factors. *Journal of Isfahan Medical School* 2011; 28(Special Issue on Hepatitis C):974-8.
19. Fadaei Nobari R, Meshkati M, Ataei B, Heidari K, Kassaian N, **Nokhodian Z**, Shoaie P, Yaran M, Adibi P. Positive hepatitis C virus antibody in Cases with History of Intravenous Drug Abuse via Community Announcement: A useful Experience. *Journal of Isfahan Medical School* 2011; 28 (Special Issue on Hepatitis C): 10-7.
20. Ataei B, Salehi M, Javadi AA, Khorvash F, Mortazavi A, Kasaian N, **Nokhodian Z**, Babak A. The Frequency of High-risk Behaviors in Intravenous Drug Abusers Referred to Addiction Prohibition Centers in Isfahan, 2010. *Journal of Isfahan Medical School* 2011; 28(114):837-42.
21. Kafashian AR, **Nokhodian Z**, Kassaian N, Babak A, Yaran M, Shoaie P, Ataei B, Adibi P. The Experience of Hepatitis C Screening among Prison Inmates with Drug Injection History in 2008-2009. *Journal of Isfahan Medical School* 2011; 28(Special Issue on Hepatitis C):29-35.
22. Meshkati M, Ataei B, **Nokhodian Z**, Yaran M, Babak A, Asgarianzadeh MR, Farshad M, Adibi P. Hepatitis C Screening in Isfahan Drop in Centers: An Experience Description. *Journal of Isfahan Medical School* 2011; 28(Special Issue on Hepatitis C):17-24.
23. Mobasherizadeh S, Kassaian N, Ataei B, **Nokhodian Z**, Adibi P. Hepatitis C Screening in Intravenous Drug Users Under Treatment with Methadone: An Action Reserch Study. *Journal of Isfahan Medical School* 2011; 28(Special Issue on Hepatitis C):36-40.
24. Ataei B, Meshkati M, Karimi A, Yaran M, Kassaian N, **Nokhodian Z**, Shoaie P, Adibi P. Hepatitis C Screening in Intravenous Drug Users in Golpayegan, Isfahan through Community Announcement: Pilot Study. *Journal of Isfahan Medical School* 2011; 28(Special Issue on Hepatitis C):1581-6.
25. Kassaian N, **Nokhodian Z**, Babak A, Ataei b, Adibi P. Hepatitis C in Patients with Multi Blood Transfusion in Isfahan, Iran. *Journal of Isfahan Medical School* 2011; 28(Special Issue on Hepatitis C):24-8.
26. Ataei B, Javadi AA, Khorvash F, Fadaei R, Zakerzadeh Z, **Nokhodian Z**, Kassaian N. Effect of Vitamin D Supplementation on the Treatment of Pulmonary Tuberculosis with Positive Sputum Smear. *Journal of Isfahan Medical School* 2011; 28 (113):781-6. 30).

27. Mostafavi SN, Ataei B, **Nokhodian Z**, Yaran M, Babak A. Seroepidemiology of *Toxoplasma gondii* infection in Isfahan province, central Iran: A population based study. *JRMS* 2011; 16 (4): 496-501.
28. Ataei B, Yazdani MR, Kalantari H, Yaran M, **Nokhodian Z**, Javadi AA, Babak A, Adibi P. Hepatitis D virus infection in Isfahan, central Iran: Prevalence and risk factors among chronic HBV infection cases. *Hepat Mon* 2011; 11(4): 269-272.
29. Etebari M, Khodarahmi GA, Jafarian-Dehkordi A, **Nokhodian Z**. Genotoxic effects of some 1-[(benzofuran-2-yl)-phenylmethyl]-imidazoles on MCF-7 cell line. *RPS* 2012; 7 (3):189-195.
30. Kassaian N, Adibi P, Kafashaian AR, Yaran M, **Nokhodian Z**, Shoaie P, Hassannejad R, Babak A, Ataei B. Hepatitis C Virus and Associated Risk Factors among Prison Inmates with History of Drug Injection in Isfahan, Iran. *IJPM* 2012; 3 (3): S156-S161.
31. Fadaei Nobari R, Meshkati M, Ataei B, Yazdani MR, Heidari K, Kassaian N, **Nokhodian Z**, Shoaie P, Yaran M, Adibi P. Identification of patients with hepatitis C virus infection in persons with background of intravenous drug use: the first community announcement-based study from Iran. *IJPM* 2012;3(3): S170-175.
32. Shoaie P, Zeidabadinejad L, Hassannejad R, Ataei B, Yaran M, Kassaian N, **Nokhodian Z**, et al. Seroprevalence of hepatitis A in patients with chronic hepatitis C in Isfahan province. *IJPM*2012; 3(3) : S102-S106.
33. Ataei B, Hashemipour M, Kassaian N, Hassannejad R, **Nokhodian Z**, Adibi P. Prevalence and risk factors of anti HCV infection in patients with beta-thalassemia in Isfahan-Iran2012; 3 (3) : S118-S123.
34. Yazdani MR, Kassaian N, Ataei B, **Nokhodian Z**, Adibi P. Hepatitis C virus infection in patients with hemophilia in Isfahan,Iran. *IJPM* 2012; 3 (3) : S89-S93.
35. **Nokhodian Z**, Meshkati M, Adibi P, Ataei B, Kassaian N, Yaran M, Shoaie P, Hassannejad R. Hepatitis C among Intravenous Drug Users in Isfahan, Iran: a Study of Seroprevalence and Risk Factors. *IJPM* 2012; 3(3): S118-S123.
36. **Nokhodian Z**, Ataei B, Kassaian N, Yaran M, Hassannejad R. Seroprevalence and risk factors of Hepatitis C virus among juveniles in correctional center in Isfahan, Iran. *IJPM* 2012; 3(3): S113-S117.
37. **Nokhodian Z**, Yazdani MR, Yaran M, Shoaie P, Mirian M, Ataei B, Babak A, Ataie M. Prevalence and Risk Factors of HIV, Syphilis, Hepatitis B and C Among Female Prisoners in Isfahan, Iran. *Hepatitis Monthly*. 2012; In Press.
38. **Nokhodian Z**, Ataei B, Babak A, Yaran M, Pahlevani A. Seroprevalence of Hepatitis A among Street Children, Isfahan, Iran. *Journal of Isfahan Medical School* 2012; 30(178): 1-7.
39. Ataei B, Khorvash F, Salehi M, Houshmand S, Kassaian N, Babak A, **Nokhodian Z**, Ataei M. The Relative Frequency of Depression and Anxiety in Patients with Hepatitis B Referring to Infectious Diseases and Tropical Medicine Research Center, Isfahan, Iran. *Journal of Isfahan Medical School* 2012; 29(169): 1-7.

40. Ataei M, **Nokhodian Z**, Ataei B, Kassaian N, Yaran M, Hassannejad R. Seroprevalence of hepatitis B virus and human immunodeficiency virus among young prisoners. *Journal of Research in Medical Sciences* 2013; 18(1): 71-73.
41. Shoaie P, Zeidabadinejad L, Ataei B, Babak A, **Nokhodian Z**, Yaran M, Kassaian N. Seroprevalence of Hepatitis A Virus in Patients with Chronic Hepatitis B or C in Isfahan Province, Iran. *Journal of Isfahan Medical School*. 2012; 30(199).
42. Ataei B, Zahraei SM, Pezeshki Z, Babak A, **Nokhodian Z**, Mobasherizadeh S, Hoseini SG. Baseline evaluation of hand hygiene compliance in three major hospitals, Isfahan, Iran. *J Hosp Infect*. ۲۰۱۳ ;۸۵(۱):۷۲-۶۹.
43. Dibaj R, Ataei B, Yaran M, **Nokhodian Z**, Tayeri K, Zamanimoghadam A. Prevalence of HIV infection in inmates with history of injection drug use and evaluation of risk factors, in Isfahan, Iran. *Pak J Med Sci* 2013;29(1) Suppl:399-402.
44. Hashemipour M, **Nokhodian Z**, Yaran M, Ataei B, Tayeri K, Nobari RF, et al. Prevalence of HIV infection in individuals with history of intravenous drug use via community announcement in Isfahan- Iran. *Pak J Med Sci* 2013; 29(1) Suppl:395-398.
45. Javadi AA, Ataei B, Yaran M, **Nokhodian Z**, Kassaian N, Tayeri K, et al. Prevalence of HIV infection and related risk factors in Isfahan Drop in Centers. *Pak J Med Sci* 2013; 29(1) Suppl:346-350.
46. **Nokhodian Z**, Yaran M, Adibi P, Kassaian N, Meshkati M, Ataei B. Seroprevalence of hepatitis B markers among incarcerate intravenous drug users. *J Res Med Sci* 2014;19: S13-S16.
47. Javadi A, Ataei B, Kassaian N, **Nokhodian Z**, Yaran M. Co-infection of human immunodeficiency virus, hepatitis C and hepatitis B virus among injection drug users in the drop-in centers. *J Res Med Sci* 2014;19: S17-S21.
48. Farajzadegan Z, Hoseini SG, Kelishadi R, Jamshidi F, **Nokhodian Z**, Noori R, Mirmoghtadaee P, Hovsepian S, Mostafavi S-N. Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran. *J Res Med Sci* 2014;19: S56-S63
49. Khodadoostan M, Ataei B, Shavakhi A, Tavakoli T, **Nokhodian Z**, Yaran M. The assessment of hepatitis B seroprevalence in persons with intravenous drug use history in the Isfahan province: Community-based study. *J Res Med Sci* 2014;19:65-8.
50. Javadi A, Adibi P, Ataei B, **Nokhodian Z**, Yaran M. Surveillance of acute respiratory infections among outpatients: A pilot study in Isfahan city. *Journal of Research in Medical Sciences* 2015;115-121
51. Ataei B, Adibi P, **Nokhodian Z**, Meshkati M, Boroumandfar Z. Prevalence of Co-Infections of Hepatitis B and C Among Drug Abuse: Prisoners and Its Association with High Risk Behavior. *Jundishapur J Chronic Dis Care*. 2015
52. Shirani K, **Nokhodian Z**, Kassaian N, Adibi P, Emami Naeini A, Atae B. The prevalence of isolated hepatitis B core antibody and its related risk factors among male injected drug users in Isfahan prisons. *Adv Biomed Res*. 2015; 4: 17.
53. Mostafavi SN, Ataei B, **Nokhodian Z**, Yaran M, Babak A, Salehi A, Haghghatian M. Seroprevalence of Cytomegalovirus infection and estimate of congenital Cytomegalovirus

- infection in Isfahan state, Iran: A population-based study. *Pak J Med Sci* 2013; 29 :418-422
54. **Nokhodian Z**, ZareFarashbandi F, Shoaie P. Mustard gas exposure in Iran-Iraq war - A scientometric study. *Journal of Education and Health Promotion* 2015; 4: 56.
  55. **Nokhodian Z**, Feizi A, Ataei B, Ghaffari Hoseini S, Mostafavi E. Epidemiology of Q fever in Iran: A systematic review and meta-analysis for estimating serological and molecular prevalence. *Journal of Research in Medical Science* 2017; 22: 121.
  56. **Nokhodian Z**, Feizi A, Moradi A, Yaran M, Ghaffari Hoseini S, Ataei B, Hosseini M. Detection and risk factors of Coxiella burnetii infection in dairy cattle based on bulk tank milk samples in center of Iran. *Preventive Veterinary Medicine* 2016; 134: 139-144.
  57. **Nokhodian Z**, Ataei B, Moradi A, Yaran M, Ghaffari Hoseini S, Feizi A, Sherkat R. Seroprevalence and risk factors of Coxiella burnetii infection among high-risk population in center of Iran, a neglected health problem. *Acta Tropica* 2017;169: 107-111.
  58. Shoaie P, Najafi S, Zeid Abadi Nejad L, Ataei B, Yaran M, **Nokhodian Z** and Vakili B. Seroprevalence of hepatitis A among individuals with chronic hepatitis B infection in Isfahan Province, Iran. *Brazilian Journal of Biological Sciences* 2015; 2: 17-21.
  59. **Nokhodian Z**, Peyman Adibi P, Ataei B. Prevalence of Hepatitis B Virus Infection in Isfahan Province. *International Journal of Preventive Medicine, hepatitis (Special issue 3)* 2014; 3:193-9.
  60. Shoaie P, Ataei B, Ataie A, **Nokhodian Z**, Adibi P. Seroprevalence of Hepatitis B and C Virus Infection Among Barbers in Isfahan Province, Iran. *Avicenna J Clin Microb Infect.* 2015; 2(3): e27147.
  61. **Nokhodian Z**, Khorvash F, Ataei B, Janghorban M. Hepatitis C virus infection in Isfahan, Iran: a review article. *Avicenna Clin Microb Infect* 2016; 3.
  62. **Nokhodian Z**, Ataei B, Khalili M, Feizi A, Moradi A, Yaran M, Ghaffari Hoseini S. Detection of Coxiella burnetii and risk factors for infection in ruminants in a central county of Iran. *Vet Microbiol* 2018; 222:7-10.
  63. **Nokhodian Z**, Feizi A, Khalili M, Ataei B, Moradi A. Molecular evidence and risk factors of Coxiella burnetii among seropositive high-risk population in center of Iran. *Comp Immunol Microbiol Infect Dis.* 2018; 61:34-37.
  64. **Nokhodian Z**, Khalili M, Ataei B, Feizi A, Moradi A, Rostami S, Yaran M. Molecular analysis of Coxiella burnetii by Isocitrate dehydrogenase (icd) gene sequence-based typing and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) in Central Iran. *World Veterinary journal.* 2019 Jun 25;9(2):52-8.
  65. **Nokhodian Z**, Ataei B, Gouya MM, Hoseini SG, Yaran M, Mansourian M, et al. A nationwide study on the seroprevalence of measles, mumps, and rubella in Iranian children and adolescents: the CASPIAN-V study. *Iranian Journal of Public Health.* 2022 Feb;51(2):409.
  66. **Nokhodian Z**, Ataei B, Zahraei SM, Gouya MM, Hoseini SG, Yaran M, et al. Seroprevalence of Bordetella pertussis among a nationally representative sample of Iranian pediatric population: The childhood and adolescence surveillance and prevention of adult noncommunicable Disease-V study. *JRMS;* 2021: 26(1).

67. **Nokhodian Z**, Ranjbar MM, Nasri P, Kassaian N, Shoaee P, Vakili B, et al. Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatment. *J Res Med Sci*. 2020 Nov 3;25.
68. Khoshgoftar M, Zamani F-, Kasaian N, Shahzamani K, Rostami S, **Nokhodian Z**, Pirzadeh A. The effect of public health educational campaign regarding antibiotic use and microbial resistance on knowledge, attitude, and practice in the Iran. *Journal of Education and Health Promotion*. 2021;10.
69. Rostami S, Gharibi S, Yaghoobi H, **Nokhodian Z**, Shoaee P, Bahrami AA, Ahangarzadeh S, Alibakhshi A. Herbal medicines as potential inhibitors of SARS-CoV-2 infection. *Current Pharmaceutical Design*. 2022 Aug 2.
70. Mostafavi SN, Rostami S, **Nokhodian Z**, Ataei B, Cheraghi A, Ataabadi P, et al. Antibacterial resistance patterns of *Acinetobacter baumannii* complex: The results of Isfahan Antimicrobial Resistance Surveillance-1 Program. *Asian Pacific Journal of Tropical Medicine*. 2021 Jul 1;14(7):316.
71. Kassaian N, Nematbakhsh S, Yazdani M, Rostami S, **Nokhodian Z**, Ataei B. Epidemiology of bloodstream infections and antimicrobial susceptibility pattern in ICU and non-ICU wards: A four-year retrospective study in Isfahan, Iran. *Advanced Biomedical Research*. 2023 Jan 1;12(1):106.
72. **Nokhodian Z**, Rostami S, Zeraatei P, Rahimkhorasani M, Abbasi S, Sadeghi S. Bacterial superinfection and antibiotic management in patients with COVID-19 admitted to intensive care medicine in central Iran: A follow-up study. *Advanced Biomedical Research*. 2023 Jan 1;12(1):43.
73. Rostami S, Javanmard SH, **Nokhodian Z**, Kassaian N, Zamani A, Tahvilian Z, Nasri P, Nasirian M, Ataei B. SARS-CoV-2 seroprevalence among health-care workers in Isfahan, Iran. *Advanced Biomedical Research*. 2023;12.
74. Shirani K, Honarjou E, Ataei B, Rostami S, **Nokhodian Z**, Shams M. Evaluation of clinical and para-clinical parameters related to disease severity and mortality in patients with influenza in Isfahan, Iran; a cross sectional study. *Immunopathol Persa*. 2023.
75. Rostami S, Kassaian N, **Nokhodian Z**, Ataei B, Zamanimoghadam A, Nasri P, et al. A process evaluation of the Isfahan antibiotic awareness campaign: Developing engagement on antimicrobial resistance. *Advanced Biomedical Research*. 2023;12.
- 76.

**Book:**

1. Author of book: "Hepatitis in Simple language", 2003, IUMS.
2. Author of book (Translation): "National Health Research System", 2002, IUMS.

**Conference Presentations:**

1. Prevalence of hepatitis B and C Virus in barbers, Isfahan (Iran), 2007. The 21st Conference of the Asian Pacific Association for the Study of the Liver. Thailand, 17-22 February 2011.
2. Anti-HCV Positivity in Cases with History of Intravenous Drug Abuse via Community Announcement: A useful Experience. The 21<sup>st</sup> Conference of the Asian Pacific Association for the Study of the Liver. Thailand, 17-22 February 2011.

3. Assessment of Quality of life in Hepatitis B patients. 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, June 19-22, 2008.
4. Assessment of Quality of Life in Hepatitis C Patients in Isfahan, Iran. 12th International Congress on Infectious Diseases, Lisbon Portugal, June 15-18, 2006.
5. Comparison of HBs-Ab serum levels between patients with Type 2 Diabetes Mellitus and Controls Following vaccination against Hepatitis B. The 1st National Congress of Endocrine & Metabolism updates, 2007, Isfahan, IRAN.
6. Correlation between HBe Ag and Alanine Aminotransferase Levels in Hepatitis B with PCR Positive Patients. 12th International Congress on Infectious Diseases, Lisbon Portugal, June 15-18, 2006.
7. Delta hepatitis infection in patients with chronic hepatitis B infection in Isfahan, Iran. 19th European Congress Microbiology and Infectious Diseases, Helsinki, Finland 16-19 may 2009.
8. HBV Markers in Central of Iran, 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, June 19-22, 2008.
9. Hepatitis C in IVDUs in Isfahan, Iran, 2008. The 21st Conference of the Asian Pacific Association for the Study of the Liver. Thailand, 17-22 February 2011.
10. Identification of patients with HCV infection in Persons with background of IVDU: The first community announcement-based study from Iran. APASL Liver Week Transforming Science to clinical Practice (Singapore).
11. Knowledge and practice about Aids. Hepatitis B and C in Barbers. 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, June 19-22, 2008.
12. Markers and risk factors of hepatitis B infection among injection drug users in Isfahan drop in centers. APASL Liver Week Transforming Science to clinical Practice (Singapore).
13. Pleural Fluid Cholesterol and Bilirubin value in Diagnostic of Exudative from Transudative pleural Effusion, 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, June 19-22, 2008.
14. Prevalence and risk factors of hepatitis B virus infection in incarcerated injection drug users in Isfahan province, Iran. APASL Liver Week Transforming Science to clinical Practice(Singapore).
15. Seroepidemiology of HEV Infection in Isfahan, Iran. A Community-Based study, 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, June 19-22, 2008.
16. Seroprevalence of hepatitis A among individuals with chronic hepatitis B infection in Isfahan Province, Iran. APASL Liver Week Transforming Science to clinical Practice(Singapore).
17. Seroprevalence of hepatitis A in patients with chronic hepatitis C in Isfahan province. APASL Liver Week Transforming Science to clinical Practice (Singapore).
18. Seroprevalence of hepatitis B and C virus infection among barbers in Isfahan, Iran. APASL Liver Week Transforming Science to clinical Practice(Singapore).

19. Seroprevalence of Hepatitis C (HCV) infection among street children in Isfahan, Iran. The 21st Conference of the Asian Pacific Association for the Study of the Liver. Thailand, 17-22 February 2011
20. The prevalence of etiologic agents of dermatophytosis in wrestlers in Isfahan, Iran. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice/ France. April 1-4 2006.
21. The prevalence of isolated Hepatitis B core antibody and its related risk factors among injection drug users in Iran. APASL Liver Week Transforming Science to clinical Practice(Singapore).
22. Risk factors for hepatitis B in Isfahan, Iran. The 1st National Congress of Endocrine & Metabolism updates, 2007, Isfahan, IRAN.

### **Gene Registration**

1. *Coxiella burnetii* clone TM20 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962682.1
2. *Coxiella burnetii* clone RA18 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962681.1
3. *Coxiella burnetii* clone JA10 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962680.1
4. *Coxiella burnetii* clone ZA25 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962679.1
5. *Coxiella burnetii* clone XM24 isocitrate dehydrogenase gene, partial cds.  
GenBank: KY962678.1
6. *Coxiella burnetii* clone WM23 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962677.1
7. *Coxiella burnetii* clone VM22 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962676.1
8. *Coxiella burnetii* clone IM9 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962675.1
9. *Coxiella burnetii* clone HA8 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962674.1
10. *Coxiella burnetii* clone GA7 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962673.1
11. *Coxiella burnetii* clone FA6 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962672.1
12. *Coxiella burnetii* clone EH5 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962671.1
13. *Coxiella burnetii* clone DH4 isocitrate dehydrogenase gene, partial cds  
GenBank: KY962670.1
14. *Coxiella burnetii* clone CH3 isocitrate dehydrogenase gene, partial cds

GenBank: KY962669.1

15. *Coxiella burnetii* clone AM1 isocitrate dehydrogenase gene, partial cds

GenBank: KY962668.1

## **Skills**

1. PCR and Real Time PCR Technique
2. Cell culture
3. Immunofluorescence assay
4. SPSS Software
5. Article writing
6. Research projects' management
7. Basics of bioinformatics basics